A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients - the ELDERS study
Lorigan, Paul C
Blackhall, Fiona H
AffiliationMedical Oncology Department, The Christie NHS Foundation Trust, Manchester
MetadataShow full item record
AbstractObjective: Older cancer patients are underrepresented in the pivotal trials of checkpoint inhibitors (CPIs). This study aimed to investigate the impact of an ageing immune system on CPI-related toxicity and provide evidence for the role of geriatric assessments with CPI. Methods: The ELDERS study is a prospective observational study with two cohorts: older (70+ years of age) and younger (<70 years of age). Patients with advanced/metastatic non-small-cell lung cancer or melanoma starting single-agent CPI were eligible. The older cohort was assessed for frailty with Geriatric-8 (G8) screening, which when positive (<15 points) was followed by a holistic set of geriatric assessments. Primary endpoint was the incidence of grade 3-5 immune-related adverse events (irAEs). Results: One hundred and forty patients were enrolled with 43% being pretreated and pembrolizumab represented 92% of treatments on study. The older cohort had a significantly higher comorbidity burden (P < 0.001) and polypharmacy (P = 0.004). While 50% of older patients had a positive G8 screening, 60% on this frail subgroup had a performance status score of 0 or 1. There was no significant difference in the incidence of irAEs grade 3-5 between older and younger cohorts (18.6% versus 12.9%; odds ratio 1.55, confidence interval 95% 0.61-3.89; P = 0.353). Exposure to systemic steroids due to irAEs was numerically longer for older patients (22 versus 8 weeks; P = 0.208). A positive G8 screening predicted hospital admissions (P = 0.031) and risk of death (P = 0.01). Conclusions: The use of CPI in older patients was not associated with more high-grade toxicity. The G8 screening identified a subgroup with higher risk of AEs and its implementation should be considered in the context of CPI.
CitationGomes F, Lorigan P, Woolley S, Foden P, Burns K, Yorke J, et al. A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients - the ELDERS study. ESMO Open. 2021;6(1):100042.
- Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients.
- Authors: Kubo T, Watanabe H, Ninomiya K, Kudo K, Minami D, Murakami E, Ochi N, Ninomiya T, Harada D, Yasugi M, Ichihara E, Ohashi K, Rai K, Fujiwara K, Hotta K, Tabata M, Maeda Y, Kiura K
- Issue date: 2020 Dec 16
- Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study.
- Authors: Espi M, Teuma C, Novel-Catin E, Maillet D, Souquet PJ, Dalle S, Koppe L, Fouque D
- Issue date: 2021 Apr
- A Tale of Immune-Related Adverse Events With Sequential Trials of Checkpoint Inhibitors in a Patient With Metastatic Renal Cell Carcinoma.
- Authors: Singh V, Chu Y, Gupta V, Zhao CW
- Issue date: 2020 Jun 1
- Risk stratification for surgical outcomes in older colorectal cancer patients using ISAR-HP and G8 screening tools.
- Authors: Souwer ETD, Verweij NM, van den Bos F, Bastiaannet E, Slangen RME, Steup WH, Hamaker ME, Portielje JEA
- Issue date: 2018 Mar
- Preoperative frailty assessment with the Robinson Frailty Score, Edmonton Frail Scale, and G8 and adverse postoperative outcomes in older surgical patients with cancer.
- Authors: Nishijima TF, Esaki T, Morita M, Toh Y
- Issue date: 2021 Apr